ADHD

Viloxazine ER (Qelbree®) Administered with Psychostimulants in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: Topline Results of a Phase IV Safety Trial

Results of a phase IV, open-label safety study evaluating viloxazine ER (Qelbree®) administered with psychostimulants in pediatric (6-17 years) ADHD; morning vs. evening administration of...

Ann Childress , MD;

10/26/2023

Qelbree® (viloxazine extended-release capsules): Final Results of the Long-Term, Phase 3, Open-Label Extension Trial in Adults With Attention-Deficit/Hyperactivity Disorder

Final results of a long-term, open-label extension of a pivotal phase 3 study leading to FDA-approval of viloxazine extended-release capsules (Qelbree®) in adults.

Andrew J. Cutler , MD;

10/26/2023

Growth Trajectories of Youth with Attention-Deficit/Hyperactivity Disorder Treated with Delayed-Release/Extended-Release Methylphenidate: A Pilot Database Analysis of Real-World Data

DR/ER-MPH is an evening-dosed delayed-release and extended-release methylphenidate that is released in the colon and provides a dose-dependent duration of effect for individuals aged ≥6y ...

Karl Weddige , PhD;

10/26/2023

Centanafadine Sustained Release in the Treatment of Adult Attention-Deficit/Hyperactivity Disorder: Secondary Outcomes From a Phase 2a Study

Centanafadine (CTN) is a norepinephrine/dopamine/serotonin reuptake inhibitor being investigated for the treatment of attention-deficit/hyperactivity disorder (ADHD). Secondary efficacy o...

Jessica McDonough , MD;

10/26/2023

52-Week Open-Label Safety and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder

Centanafadine (CTN) is a novel norepinephrine/dopamine/serotonin reuptake inhibitor in development for attention-deficit/hyperactivity disorder (ADHD). Long-term (52 weeks) safety and exp...

Jessica McDonough , MD;

10/26/2023

A Phase 3, safety and efficacy, adult laboratory classroom study in subjects with Attention-Deficit/Hyperactivity Disorder (ADHD) using CTx-1301 (dexmethylphenidate).

Cingulate has conducted a Phase 3 randomized, placebo controlled efficacy and safety study along with onset and duration in 21 adults with ADHD using CTx-1301 in a laboratory classroom se...

Ann Childress , MD;

10/26/2023

A Randomized, Five-Way Crossover Study to Evaluate Bioequivalence of the Dextroamphetamine Transdermal System (d-ATS) at Five Application Sites in Healthy Adults

In a pivotal study, d-ATS applied to the hip met primary and secondary efficacy endpoints for ADHD in children and adolescents. In this open-label crossover study, healthy adults were ran...

Mahwish Khan , PharmD, RPh;

10/26/2023

A Thorough QT Trial Using C-QTc to Evaluate the Effects of Centanafadine on Cardiac Repolarization

Centanafadine is a norepinephrine/dopamine/serotonin reuptake inhibitor in development for treatment of attention-deficit/hyperactivity disorder (ADHD). The effect of centanafadine on car...

Osman Turkoglu , MD;

10/26/2023

.more-link-label { color: #000; } .st0 { fill: #000; }

Videos

Understanding the Stimulant Shortage

09/05/2023

Greg Mattingly, MD

Dr Mattingly explains the stimluant shortage and what clinicians can do to help their patients.

Dr Mattingly explains the...

09/05/2023

Psych Congress Network

Viloxazine Extended-Release Capsules (Qelbree®) for Adults with Attention-Deficit/Hyperactivity Disorder: Evaluating the Potential Impact of Caffeine Exposure on Safety Profile

Abstract: Viloxazine ER (viloxazine extended-release capsules, Qelbree®) is a novel, nonstimulant, FDA-approved treatment for adults and children (≥6 yrs) with ADHD. Viloxazine ER inhibit...

Jami Earnest ;

Azmi Nasser , PhD;

01/19/2023

A Retrospective Real-World Analysis Demonstrating the Value of Azstarys for Patients With Attention-Deficit Hyperactivity Disorder

Abstract: Aim: To quantify the value of Azstarys (serdexmethylphenidate/dexmethylphenidate) for patients with attention-deficit hyperactivity disorder (ADHD) with real-world data from the...

Meg Corliss ;

Mary Wiggin ;

01/19/2023

Serdexmethylphenidate/Dexmethylphenidate for Children With Attention-Deficit Hyperactivity Disorder: Reduction in Disorder Severity From a Laboratory Classroom Study

Abstract: Aim: To evaluate changes in attention-deficit hyperactivity disorder (ADHD) severity in children (aged 6-12 years) posttreatment with serdexmethylphenidate/dexmethylphenidate (S...

Matthew Brams ;

Mary Wiggin ;

01/19/2023

The Impact of Long-Term Treatment with Viloxazine Extended-Release Capsules (Qelbree®) on Executive Function in Adults with Attention-Deficit/Hyperactivity Disorder

Abstract: Viloxazine ER is a novel, nonstimulant, FDA-approved treatment for ADHD in children and adults (≥ 6 years). Viloxazine ER effects on executive function (EF) deficits were evalua...

Azmi Nasser , PhD;

01/19/2023

Interim Analysis of Efficacy During Long-Term Treatment with Viloxazine Extended-Release Capsules (Qelbree®) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder

Abstract: Viloxazine ER (Qelbree®) is a novel, nonstimulant, FDA-approved treatment for ADHD in pediatric patients (≥6 years) and adults. The efficacy of viloxazine ER was evaluated in 4 ...

Azmi Nasser , PhD;

01/19/2023

A Model-Based Pharmacokinetic Comparison of Delayed-Release/Extended-Release Methylphenidate to Extended-Release Methylphenidates with Immediate-Release Supplementation

Abstract: Purpose: Immediate-release methylphenidate (IR MPH) is sometimes dosed in the afternoon to extend the duration of effect of a morning-dosed extended-release (ER) MPH for attenti...

Cassandra Uchida ;

Karl Weddige , PhD;

01/19/2023

Effect Size and NNT of the Dextroamphetamine Transdermal System (d-ATS) for ADHD in Children and Adolescents: Post-Hoc Analysis of a Pivotal Study

Abstract: Background: In a pivotal study, the dextroamphetamine transdermal system (d-ATS) met primary and secondary efficacy endpoints for ADHD in children and adolescents. This post-hoc...

Andrew J. Cutler , MD;

Peg Bader ;

01/19/2023

Serdexmethylphenidate/Dexmethylphenidate Effects on Sleep in Children With Attention-Deficit Hyperactivity Disorder

Abstract: Aim: To determine sleep behavior during serdexmethylphenidate/dexmethylphenidate (SDX/d-MPH) treatment in children with attention-deficit hyperactivity disorder (ADHD). Method...

Mary Wiggin ;

Greg Mattingly , MD;

01/19/2023

Interpreting Improvements in Emotional Lability with Delayed-Release and Extended-Release Methylphenidate Treatment in Children with Attention-Deficit/Hyperactivity Disorder

Abstract: Purpose: Emotional lability (EL) is commonly seen in individuals with attention-deficit/hyperactivity disorder (ADHD). A post hoc analysis found that DR/ER-MPH (formerly HLD200)...

Justin Barnes ;

Cassandra Uchida ;

01/19/2023

About

Celebrating 39 years of empowering the highest standard in mental healthcare, Psych Congress serves as a unique, integrated forum to connect members of the entire mental health team—bringing together psychiatrists, nurse practitioners, physician associates, psychologists, primary care physicians, and other mental health professionals for practical education to improve patient care.